Neuronetics Azione

Neuronetics Debiti verso fornitori

Il Debiti Commerciali di Neuronetics (STIM) al 16 ago 2026 è 10,74 Mio. USD. L'anno precedente, Debiti Commerciali era 11,08 Mio. USD — una variazione del -3,05% (inferiore).

Debiti verso fornitori

10,74 Mio.USD

YoY

-3,05%

Ultimo aggiornamento:

Debiti Commerciali di Neuronetics ammonta a 2026 10,74 Mio. USD. Debiti Commerciali di Neuronetics ammontava a 2025 11,08 Mio. USD. Diminuisce del -3,05% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Neuronetics Analisi delle Azioni

Cosa fa Neuronetics? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Neuronetics azioni

Debiti Commerciali di Neuronetics è 10,74 Mio. USD nel 2026.

Il Debiti Commerciali di Neuronetics è passato da 11,08 Mio. USD a 10,74 Mio. USD, con una variazione del -3,05 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Neuronetics di Debiti Commerciali dal 2006, con valori annuali, grafici e analisi dettagliate.

I debiti commerciali rappresentano il denaro dovuto ai fornitori per beni e servizi ricevuti. È un componente fondamentale della gestione del capitale di esercizio.

Il USD di Debiti Commerciali è un fattore chiave per gli investitori. I cambiamenti in questa metrica possono segnalare il miglioramento o il deterioramento dei fondamentali, impattando direttamente il prezzo delle azioni. Su Eulerpool puoi tracciare il Neuronetics di Debiti Commerciali storicamente e in tempo reale.

Access this data via the Eulerpool API

Bilancio — Neuronetics

Tutte le Metriche Finanziarie — Neuronetics